| » View all news titles |
» View titles this week |
» View titles this month |
3/20/2015
Working with cells taken from children with a very rare but aggressive form of brain cancer, Johns Hopkins Kimmel Cancer Center scientists have identified a genetic pathway that acts as a master regulator of thousands of genes, and may spur cancer cell growth and resistance to anticancer treatment. Their work was published in Oncotarget and the Journal of Neuropathology and Experimental Neurology.
Their experiments with cells from patients with atypical teratoid/rhabdoid tumor also found that selumetinib, an experimental anticancer drug currently in clinical trials for other childhood brain cancers, can disrupt part of the molecular pathway regulated by one of these factors, according to a research team led by Eric Raabe, MD, PhD, Assistant Professor of Oncology at the Johns Hopkins University School of Medicine.
